The trading price of Autolus Therapeutics plc ADR (NASDAQ:AUTL) closed lower on Friday, April 19, closing at $4.52, -5.83% lower than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $7.45 and a 52-week low of $1.61. Over the past month, the stock has lost -30.99% in value.
Autolus Therapeutics plc ADR, whose market valuation is $786.93 million at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.05 per share this quarter, however they have predicted annual earnings per share of -$0.71 for 2024 and -$0.59 for 2025. It means analysts are expecting annual earnings per share growth of 40.80% this year and 16.90% next year.
Analysts have forecast the company to bring in revenue of $16.67 million for the current quarter, with the likely lows of -$ and highs of $50 million. The average estimate suggests sales will likely up by 1,190.20% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2024 is $36.88 million. The company’s revenue is forecast to grow by 2,072.00% over what it did in 2024.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Autolus Therapeutics plc ADR no upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest AUTL has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently Hold.
A quick review shows that AUTL’s price is currently -18.73% off the SMA20 and -23.55% off the SMA50. The RSI metric on the 14-day chart is currently showing 27.99, and weekly volatility stands at 6.84%. When measured over the past 30 days, the indicator reaches 6.20%. Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s beta value is currently sitting at 1.97, while the Average True Range indicator is currently displaying 0.35.
To see how Autolus Therapeutics plc ADR stock has been performing in comparison to its peers in the industry, here are the numbers: AUTL stock’s performance was -5.83% in the latest trading, and 144.32% in the past year.
An evaluation of the daily trading volume of Autolus Therapeutics plc ADR (NASDAQ:AUTL) indicates that the 3-month average is 1.55 million.
Currently, records show that 174.10 million of the company’s shares remain outstanding. The insiders hold 9.38% of outstanding shares, whereas institutions hold 61.01%. However, since the stock’s price has seen -29.81% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
